For example, PDGFRA-targeted therapies, such as avapritinib, have shown efficacy in models with PDGFRA amplification (NCT04773782), while hemispheric gliomas harboring the G34R mutation, along with the PDGFRA C235Y variant, respond to infigratinib [72,209,210]. The gene discussed is PDGFRA; the disease is central nervous system cancer.